Skip to content
The Nexus
DossierENTITY

drug-pricing policies

Coverage of drug-pricing policies in the Nexus archive.

Earliest in view: Jun 10 · 14:31 UTCMost recent: Jun 10 · 14:31 UTC
Co-mentioned in this coverage
Sanofiorganization1riliprubarttopic1Parabilis Medicinesorganization1European countriesplace1STAT+organization1
Recent coverage
  • BUSINESSJun 10 · 14:31 UTCSTAT NEWS
    STAT+: Hope for Kendall Square’s lab market

    Sanofi halted a Phase 3 study of its drug riliprubart due to lack of efficacy, while Parabilis Medicines raised $670 million in a record biotech IPO. European countries face conflicts over drug-pricing policies amid budget strains and U.S. pressure.